Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

News

 

EQT exits ImCheck Therapeutics following Ipsen’s €1 billion acquisition deal

EQT Life Sciences, the healthcare investment arm of Swedish private equity firm EQT, has exited Marseille-based biotech ImCheck Therapeutics. ImCheck, which develops immuno-oncology therapies targeting butyrophilins, a novel family of immune-regulating proteins, has agreed to be acquired by Paris-headquartered biopharmaceutical company Ipsen in a deal worth up to €1 billion. The deal underscores growing interest in European immunotherapy innovation, driven by patent cliff pressures, favourable valuation dynamics compared to US assets, and Europe’s maturing research ecosystem, which now produces around 40% of global scientific citations.
October 23, 2025

Smart ring maker Ōura raises $900 million

Finnish health tracking ring maker Ōura has raised over $900 million in a funding round led by US-based asset manager Fidelity Management, with participation from new investor ICONIQ, based in California, and existing backers Whale Rock and Atreides, both Boston-based investment firms
October 23, 2025

UK’s CoMind raises $100m+ to advance non-invasive brain monitoring

CoMind, a London-based medtech start-up, has raised more than $100 million to advance its non-invasive brain monitoring technology, with the latest $60 million round led by Plural, a London-based early-stage venture fund.  Industry sources have told HBI that the minimally invasive and implantable medtech sector is particularly attractive. It offers strong dual appeal: improving patient outcomes while enhancing operational efficiency through automation and workforce optimisation.
October 23, 2025

FREE BLOG Could European drug prices increase following Trump’s pharma policy? 

Earlier this month, The Trump administration launched TrumpRx.gov, a government website that allows consumers to purchase prescription drugs directly. The move is part of a broader overhaul of US pharmaceutical policy, which includes letters sent to 17 drugmakers demanding lower domestic prices and the enforcement of the Most Favoured Nation (MFN) (lowering US drug prices to those in other developed countries).
October 23, 2025

Bupa acquires third London hospital

British multinational health insurer Bupa is buying King Edward VII’s Hospital, a 56-bed facility in the Harley Street area in London. This follows the recent acquisition of New Victoria Hospital, a 33-bed facility in Kingston Upon Thames. Both acquisitions are driven by Bupa’s strategic intent to keep 40% of referrals within its provider network. However, we hear Bupa may struggle to attract the consultants, and therefore enough patients, that would be required to achieve this.
October 23, 2025

Interview: Andrew Neville, Inflexion

Inflexion is a European mid-market private equity firm that invests in multiple healthcare sub sectors — medical devices, outsourced pharma services, specialty pharma products and animal health. In a conversation with HBI, Andrew Neville, Partner, explained what Inflexion is looking for in the businesses it invests in, and offers case studies of two companies currently in its portfolio.
October 17, 2025

Fresenius accelerates Vamed sell-off

Healthcare conglomerate Fresenius Group has decided to split the sale of the Austrian branch of subsidiary Vamed into two steps, in order to simplify and accelerate the process. 
October 16, 2025
Older posts
Newer posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us